Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TESLA: Evolocumab in Homozygous Familial Hypercholesterolemia
NCT01588496Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2012
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of evolocumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Amgen. Started Apr 2012; status: completed.
02
Drugs
evolocumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT01588496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01588496.